Cited by 7,810Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Open access

Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Bouché, Olivier, Guimbaud, Rosine, Bécouarn, Yves, Adenis, Antoine, Raoul, Jean-Luc, Gourgou-Bourgade, Sophie, de la Fouchardière, Christelle, Bennouna, Jaafar, Bachet, Jean-Baptiste, Khemissa-Akouz, Faiza, Péré-Vergé, Denis, Delbaldo, Catherine, Assenat, Eric, Chauffert, Bruno, Michel, Pierre, Montoto-Grillot, Christine, Ducreux, Michel·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1011923

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS: The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS: As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011923

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

Zeghari-Squalli N, 1999, Clin Cancer Res, 5, 1189
10.2307/2281868 · DOI · Paper page
Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.

Sorted by citations

Items 401–500 of 1,032

Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 132
Chemotherapy and radiotherapy for advanced pancreatic cancer
Chin, V. T., Nagrial, A. M., Sjoquist, K. M., O'Connor, C. A., Chantrill, L. A., Biankin, A. V., Scholten, R. J. P. M., & Yip, D. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011044.pub2 · Cited by 131
Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging
Lu, G., Shang, W., Deng, H., Han, Z., Hu, M., Liang, X., Fang, C., Zhu, X., Fan, Y., & Tian, J. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.025 · Cited by 130
Pancreatic cancer: A comprehensive review and update
Muniraj, T., Jamidar, P. A., & Aslanian, H. R. (2013) · Disease-a-Month · doi:10.1016/j.disamonth.2013.08.001 · Cited by 132
Re-resection for Isolated Local Recurrence of Pancreatic Cancer is Feasible, Safe, and Associated with Encouraging Survival
Strobel, O., Hartwig, W., Hackert, T., Hinz, U., Berens, V., Grenacher, L., Bergmann, F., Debus, J., Jäger, D., Büchler, M. W., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2762-z · Cited by 129
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv264 · Cited by 129
Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
Alexander, M. S., Wilkes, J. G., Schroeder, S. R., Buettner, G. R., Wagner, B. A., Du, J., Gibson-Corley, K. N., O’Leary, B. R., Spitz, D. R., Buatti, J. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1680 · Cited by 129
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Liu, X., Jiang, J., Liao, Y., Tang, I., Zheng, E., Qiu, W., Lin, M. J., Wang, X., Ji, Y. C., Mei, K., et al. (2021) · Advanced Science · doi:10.1002/advs.202002147 · Cited by 129
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
Markowitz, J., Brooks, T., Duggan, M. C., Paul, B. K., Pan, X. J., Wei, L., Abrams, Z. B., Luedke, E. A., Lesinski, G. B., Mundy-Bosse, B. L., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1618-8 · Cited by 131
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Pearson, R. K. (2011) · Yearbook of Gastroenterology · doi:10.1016/j.ygas.2011.07.138 · Cited by 128
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Cook, N., Basu, B., Smith, D. M., Gopinathan, A., Evans, J., Steward, W. P., Palmer, D. H., PROPPER, D. J., Venugopal, B., Hategan, M., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.495 · Cited by 129
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Kang, J., Hwang, I., Yoo, C., Kim, K., Jeong, J. H., Chang, H.-M., Lee, S. S., Park, D. H., Song, T. J., Seo, D. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0598-5 · Cited by 131
Analysis of Endoscopic Radiofrequency Ablation of Biliary Malignant Strictures in Pancreatic Cancer Suggests Potential Survival Benefit
Kallis, Y. N., Phillips, N., Steel, A., Kaltsidis, H., Vlavianos, P., Habib, N., & Westaby, D. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3731-8 · Cited by 128
Therapeutic options for the management of pancreatic cancer
Rossi, M. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11142 · Cited by 130
Targeting mTOR dependency in pancreatic cancer
Morran, D. C., Wu, J., Jamieson, N. B., Mrowinska, A., Kalna, G., Karim, S. A., Au, A. Y. M., Scarlett, C. J., Chang, D. K.-F., Pajak, M. Z., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306202 · Cited by 127
The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells
Blanco, F. F., Jimbo, M., Wulfkuhle, J. D., Gallagher, R. I., Deng, J., Enyenihi, L., Meisner-Kober, N. C., Londin, E. R., Rigoutsos, I., Sawicki, J. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.325 · Cited by 131
LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway
Zhan, H., Wang, Y., Li, C., Xu, J., Zhou, B., Zhu, J., Han, H., Wang, L., Wang, Y., & Hu, S. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.018 · Cited by 128
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 134
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
Gresham, G. K., Wells, G. A., Gill, S., Cameron, C., & Jonker, D. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-471 · Cited by 126
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
Awasthi, N., Zhang, C., Schwarz, A. M., Hinz, S., Wang, C., Williams, N. S., Schwarz, M. A., & Schwarz, R. E. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt227 · Cited by 126
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy
Lowery, M. A., Klimstra, D. S., Shia, J., Yu, K. H., Allen, P. J., Brennan, M. F., & O'Reilly, E. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0231 · Cited by 126
Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
Frigerio, I. M., Regi, P., Giardino, A., Scopelliti, F., Girelli, R., Bassi, C., Gobbo, S., Martini, P. T., Capelli, P., D’Onofrio, M., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5885-4 · Cited by 126
Xanthohumol inhibits angiogenesis by suppressing nuclear factor‐κB activation in pancreatic cancer
Saito, K., Matsuo, Y., Imafuji, H., Okubo, T., Maeda, Y., Sato, T., Shamoto, T., Tsuboi, K., Morimoto, M., Takahashi, H., et al. (2017) · Cancer Science · doi:10.1111/cas.13441 · Cited by 129
Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer
Liu, X., Jiang, J., Chan, R., Ji, Y. C., Lu, J., Liao, Y., Okene, M. O., Lin, J., Lin, P. K., Chang, C. H., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06164 · Cited by 128
Pancreatic Cancer and Immunotherapy: A Clinical Overview
Timmer, F. E. F., Geboers, B., Nieuwenhuizen, S., Dijkstra, M., Schouten, E. A. C., Puijk, R. S., de Vries, J. J. J., van den Tol, M. P., Bruynzeel, A. M. E., Streppel, M. M., et al. (2021) · Cancers · doi:10.3390/cancers13164138 · Cited by 129
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 129
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
Hong, J. Y., Nam, E. M., Lee, J., Park, J. O., Lee, S., Song, S.-Y., Choi, S. H., Heo, J. S., Park, S. H., Lim, H. Y., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2328-1 · Cited by 125
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
Gurka, M. K., Collins, S. P., Slack, R. S., Tse, G., Charabaty, A., Ley, L., Berzcel, L., Lei, S., Suy, S., Haddad, N., et al. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-44 · Cited by 125
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer
Chen, K., Qian, W., Jiang, Z., Cheng, L., Li, J., Sun, L., Zhou, C., Gao, L., Lei, M., Yan, B., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0701-0 · Cited by 125
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials
Ciliberto, D., Botta, C., Correale, P., Rossi, M., Caraglia, M., Tassone, P., & Tagliaferri, P. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.019 · Cited by 124
Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer
Peixoto, R. D., Speers, C. H., McGahan, C. E., Renouf, D. J., Schaeffer, D. F., & Kennecke, H. F. (2015) · Cancer Medicine · doi:10.1002/cam4.459 · Cited by 126
Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection
Tee, M. C., Krajewski, A. C., Groeschl, R. T., Farnell, M. B., Nagorney, D. M., Kendrick, M. L., Cleary, S. P., Smoot, R. L., Croome, K. P., & Truty, M. J. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.05.001 · Cited by 126
Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer
Strobel, O., Berens, V., Hinz, U., Hartwig, W., Hackert, T., Bergmann, F., Debus, J., Jäger, D., Büchler, M. W., & Werner, J. (2012) · Surgery · doi:10.1016/j.surg.2012.05.029 · Cited by 124
Circulating tumor cells in pancreatic cancer patients: Methods of detection and clinical implications
Tjensvoll, K., Nordgård, O., & Smaaland, R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28134 · Cited by 123
Tumour–stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies
Heinemann, V., Reni, M., Ychou, M., Richel, D. J., Macarulla, T. M., & Ducreux, M. P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.004 · Cited by 123
Self-citation
Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis
Xin Min, Z. H. O. U., Lu, Z., Wang, T., Huang, Z., Zhu, W., & Miao, Y. (2018) · Gene · doi:10.1016/j.gene.2018.06.037 · Cited by 123
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Wang‐Gillam, A., Lim, K., McWilliams, R. R., Suresh, R., Lockhart, A. C., Brown, A., Breden, M. A., Belle, J. I., Herndon, J. M., Bogner, S. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0308 · Cited by 128
Malignant biliary obstruction: From palliation to treatment
Boulay, B. R., & Birg, A. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i6.498 · Cited by 122
A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review
Fogel, E. L., Shahda, S., Sandrasegaran, K., DeWitt, J. M., Easler, J. J., Agarwal, D. M., Eagleson, M. A., Zyromski, N. J., House, M. G., Ellsworth, S. G., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.610 · Cited by 122
LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker
Bressy, C., Lac, S., Nigri, J., Leca, J., Roques, J., Lavaut, M., Secq, V., Guillaumond, F., Bui, T.-T., Pietrasz, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-2790 · Cited by 121
Self-citation
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
Schwarz, L., Vernerey, D., Bachet, J., Tuech, J., Portales, F., Michel, P., & Cunha, A. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4663-4 · Cited by 121
Self-citation
How I treat cancer-associated anemia
Gilreath, J. A., & Rodgers, G. M. (2020) · Blood · doi:10.1182/blood.2019004017 · Cited by 126
The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 134
Chemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120
Prognostic and predictive markers in pancreatic adenocarcinoma
Le, N. N. H., Sund, M., Vinci, A., Beyer, G., Javed, M., Krug, S., Neessee, A., & Schober, M. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.11.001 · Cited by 122
Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo
Mardhian, D. F., Storm, G., Bansal, R., & Prakash, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.031 · Cited by 122
Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer
Zhang, K., Hua, Y., Wang, D., Chen, L., Wu, C., Chen, Z., Liu, L., & Chen, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1782-x · Cited by 121
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Tempero, M. A., Oh, D., Tabernero, J. M., Reni, M., Cutsem, E. V., Hendifar, A. E., Waldschmidt, D., Starling, N., Bachet, J., Chang, H. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.070 · Cited by 122
Self-citation
Targeting cancer cell metabolism in pancreatic adenocarcinoma
Cohen, R., Neuzillet, C., Tijeras‐Raballand, A., Faivre, S. J., Gramont, A. D. E., & Raymond, É. (2015) · Oncotarget · doi:10.18632/oncotarget.4160 · Cited by 119
Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies
Rucki, A. A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2237 · Cited by 119
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
Heinemann, V., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302759 · Cited by 119
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
Heinemann, V., Haas, M., & Boeck, S. H. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt239 · Cited by 119
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Ko, A. H., Bekaii‐Saab, T., Ziffle, J. V., Mirzoeva, O. K., Joseph, N. M., Talasaz, A. H., Kühn, P., Tempero, M. A., Collisson, E. A., Kelley, R. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0979 · Cited by 121
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Pusceddu, S., Ghidini, M., Torchio, M., Corti, F., Tomasello, G., Niger, M., Prinzi, N., Nichetti, F., Coinu, A., Bartolomeo, M. D., et al. (2019) · Cancers · doi:10.3390/cancers11040484 · Cited by 122
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Varghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 122
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
de Geus, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S. C., Kent, T. S., Mancias, J. D., Callery, M. P., Mahadevan, A., & Tseng, J. F. (2017) · Cancer · doi:10.1002/cncr.30856 · Cited by 118
Current Standards of Chemotherapy for Pancreatic Cancer
Saung, M. T., & Zheng, L. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.015 · Cited by 122
Advances in pancreatic cancer biomarkers
Hasan, S. M., Jacob, R., Manne, U., & Paluri, R. K. (2019) · Oncology Reviews · doi:10.4081/oncol.2019.410 · Cited by 124
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer
Seppälä, T. T., Zimmerman, J. W., Sereni, E., Plenker, D., Suri, R., Rozich, N., Blair, A. B., Thomas, D. L., Teinor, J. A., Javed, A. A., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004200 · Cited by 122
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 126
Photosensitizer Nanoparticles Boost Photodynamic Therapy for Pancreatic Cancer Treatment
Yang, H., Liu, R., Xu, Y., Qian, L., & Dai, Z. (2021) · Nano-Micro Letters · doi:10.1007/s40820-020-00561-8 · Cited by 118
Para-aortic lymph node sampling in pancreatic head adenocarcinoma
Schwarz, L., Lupinacci, R. M., Svrcek, M., Lesurtel, M., Bubenheim, M., Vuarnesson, H., Balladur, P., & Paye, F. (2014) · British journal of surgery · doi:10.1002/bjs.9444 · Cited by 117
Incidence, Prognosis, and Possible Treatment Strategies of Peritoneal Carcinomatosis of Pancreatic Origin
Thomassen, I., Lemmens, V. E. P. P., Nienhuijs, S. W., Luyer, M. D. P., Klaver, Y. L. B., & de Hingh, I. H. J. T. (2012) · Pancreas · doi:10.1097/mpa.0b013e31825abf8c · Cited by 117
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Chou, A. S. Y., Froio, D., Nagrial, A. M., Parkin, A., Murphy, K. J., Chin, V. T., Wohl, D., Steinmann, A. M., Stark, R., Drury, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315144 · Cited by 121
Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence
O'Reilly, D. A., Fou, L., Hasler, E., Hawkins, J. E., O'Connell, S. M., Pelone, F., Callaway, M. P., Campbell, F., Capel, M. M., Charnley, R., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.09.012 · Cited by 120
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Samuel, N., & Hudson, T. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.215 · Cited by 117
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
Hage, C., Rausch, V., Giese, N. A., Giese, T., Schönsiegel, F., Labsch, S., Nwaeburu, C. C., Mattern, J., Gladkich, J., & Herr, I. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.158 · Cited by 118
Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival
Burkhart, R. A., Yu, P., Norris, Z. A., Tholey, R. M., Talbott, V. A., Liang, Q., Ai, Y., Miller, K., Lal, S., Cozzitorto, J. A., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0699 · Cited by 116
Stromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 119
Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients
Kluger, M. D., Epelboym, I., Schrope, B., Mahendraraj, K., Hecht, E. M., Susman, J., Weintraub, J. L., & Chabot, J. A. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5034-x · Cited by 118
Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues
Chang, Q., Ornatsky, O., Siddiqui, I. F. S., Straus, R., Baranov, V. I., & Hedley, D. W. (2016) · Scientific Reports · doi:10.1038/srep36641 · Cited by 116
Preoperative predictors for early recurrence of resectable pancreatic cancer
Nishio, K., Kimura, K., Amano, R., Yamazoe, S., Ohrira, G., Nakata, B., Hirakawa, K., & Ohira, M. (2017) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-1078-z · Cited by 117
Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells
Zarei, M., Lal, S., Parker, S. J., Nevler, A., Gohar, A. V., Dukleska, K., Mambelli-Lisboa, N. C., Moffat, C., Blanco, F. F., Chand, S. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0015 · Cited by 119
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Rech, A. J., Dada, H., Kotzin, J. J., Henao‐Mejia, J., Minn, A. J., Victor, C. T.-S., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3821 · Cited by 117
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A. R., Desai, A., Moore, K. M., Jamieson, N. B., Chang, D. K.-F., Bailey, P. J., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5320 · Cited by 116
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02511 · Cited by 118
Trial watch
Vacchelli, E., Galluzzi, L., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.2.19026 · Cited by 122
Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer
Mutgan, A. C., Besikcioglu, H. E., Wang, S., Frieß, H., Ceyhan, G. O., & Demir, İ. E. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0806-0 · Cited by 117
Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study
Roberts, K. J., Bannister, C. A., & Schrem, H. (2018) · Pancreatology · doi:10.1016/j.pan.2018.10.010 · Cited by 116
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Brunner, M., Wu, Z., Krautz, C., Pilarsky, C. P., Grützmann, R., & Weber, G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184543 · Cited by 121
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy
Canè, S., Barouni, R. M., Fabbi, M., Cuozzo, J. W., Fracasso, G., Adamo, A., Ugel, S., Trovato, R., Sanctis, F. D., Giacca, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6221 · Cited by 120
Advances in the management of pancreatic cancer
Chiaro, M. D., Sugawara, T., Karam, S. D., & Messersmith, W. A. (2023) · BMJ · doi:10.1136/bmj-2022-073995 · Cited by 118
Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells
Tréhoux, S., Lahdaoui, F., Delpu, Y., Renaud, F., Leteurtre, E., Torrisani, J., Jonckheere, N., & SEUNINGEN, I. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.033 · Cited by 115
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Oddo, J., Vitek, M. P., Lopez, C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0542 · Cited by 114
Multiple Layer‐by‐Layer Lipid‐Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models
Li, F., Zhao, X. L., Wang, H., Zhao, R., Ji, T., Ren, H., Anderson, G. J., Nie, G., & Hao, J. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201401583 · Cited by 117
A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma
Hong, T. S., Ryan, D. P., Borger, D. R., Blaszkowsky, L. S., Yeap, B. Y., Ancukiewicz, M., Deshpande, V., Shinagare, S. A., Wo, J. Y.-L., Boucher, Y., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.03.034 · Cited by 114
Biomarkers in Pancreatic Cancer
Fong, Z. V., & Winter, J. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827654ea · Cited by 116
Stromal expression of SPARC in pancreatic adenocarcinoma
Neuzillet, C., Tijeras‐Raballand, A., Cros, J. F., Faivre, S. J., Hammel, P. R., & Raymond, É. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9439-3 · Cited by 114
CAR T‐cell therapy for pancreatic cancer
DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24627 · Cited by 116
Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting
Pothuraju, R., Rachagani, S., Junker, W. M., Chaudhary, S., Saraswathi, V., Kaur, S., & Batra, S. K. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0963-4 · Cited by 119
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
Wang, J. P., Wu, C., Yeh, Y.-C., Shyr, Y., Wu, Y.-Y., Kuo, C., Hung, Y., Chen, M., Lee, W., Luo, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4216 · Cited by 115
Multi-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma
Peddi, P. F., Lubner, S. J., McWilliams, R. R., Tan, B. R., Picus, J., Sorscher, S. M., Suresh, R., Lockhart, A. C., Wang, J., Menias, C. O., et al. (2012) · PubMed · doi:10.6092/1590-8577/913 · Cited by 113
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
Chand, S. N., O’Hayer, K., Blanco, F. F., Winter, J. M., & Brody, J. R. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14951 · Cited by 117
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis
Satoi, S., Fujii, T., Yanagimoto, H., Motoi, F., Kurata, M., Takahara, N., Yamada, S., Yamamoto, T., Mizuma, M., Honda, G., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001705 · Cited by 114
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
Hecht, J. R., Lonardi, S., Bendell, J. C., Sim, H., Macarulla, T. M., Lopez, C. D., Cutsem, E. V., Martín, A. J. M., Park, J. O., Greil, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02232 · Cited by 116
Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma
Cloyd, J. M., Wang, H., Egger, M. E., Tzeng, C.-W. D., Prakash, L. R., Maitra, A., Varadhachary, G. R., Shroff, R., Javle, M., Fogelman, D., et al. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.2227 · Cited by 112
Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: Is it worthwhile?
Miyazaki, M., Yoshitomi, H., Shimizu, H., Ohtsuka, M., Yoshidome, H., Furukawa, K., Takayasiki, T., Kuboki, S., Okamura, D., Suzuki, D., et al. (2013) · Surgery · doi:10.1016/j.surg.2013.06.050 · Cited by 112

Authors: Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.-B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M.
Affiliations: Centre Léon Bérard (FR)
Centre Hospitalier Universitaire de Reims (FR)
Institut Claudius Regaud (FR)
Institut Bergonié (FR)
Centre Oscar Lambret (FR)
Centre Eugène Marquis (FR)
Hôpital Ambroise-Paré (FR)
Centre Hospitalier de Perpignan (FR)
Hôpital de la Croix-Rousse (FR)
Centre Hospitalier Universitaire Henri-Mondor (FR)
Centre Georges François Leclerc (FR)
Université de Rouen Normandie (FR)
UniCancer Group (FR)
Institut Gustave Roussy (FR)
ORCID: Conroy, Thierry
Ychou, Marc
Bouché, Olivier
Guimbaud, Rosine
Adenis, Antoine
Raoul, Jean-Luc
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-05-12
Volume: 364
Issue: 19
Pages: 1817-1825
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1011923
OpenAlex: W2151253787
Cited by: 7,810
References: 37
Citations by year: 2026: 425 · 2025: 521 · 2024: 560 · 2023: 604 · 2022: 622 · 2021: 785 · 2020: 692 · 2019: 563 · 2018: 577 · 2017: 558 · 2016: 454 · 2015: 473 · 2014: 388 · 2013: 282 · 2012: 222
FWCI: 150.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: FOLFIRINOX, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, overall survival, progression-free survival, objective response rate, febrile neutropenia, quality of life, adverse events, combination chemotherapy, randomized trial comparison
MeSH terms: Irinotecan, Oxaliplatin, Gemcitabine, Adenocarcinoma, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Pancreatic Neoplasms, Quality of Life, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks